AVDL Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.37%, SMA50 0.63%, SMA200 40.81%). The stock’s 14-day RSI is 60.81 (firm momentum), while the ATR of 0.09 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -8.23% below its high and over 239.03% above its low. Average 10-day trading volume of 1.59 million shares is below the 3-month average of 1.90 million, indicating normal recent market interest.

Avadel Pharmaceuticals plc has 98.15 million shares outstanding. The public float is 81.00 million shares, elevated short interest at 2.81% of float. This equals 2.73 million shares. The short ratio is 1.78 days. Institutional investors hold 99.42% of the float. Insiders own 4.84%. Broadfin Healthcare Master Fund Ltd holds 4.13 million shares, Flynn James E has 952.26 thousand shares and ANDERSON MICHAEL S has 248.95 thousand shares.

Avadel Pharmaceuticals plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.60. This means the shares are trading below this model’s fair value.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) closed at $21.63 USD, gaining $0.01 (0.05%) from the previous close of $21.62. The stock is currently mid-range between its 52-week high and low $6.38 and $23.57. With a market capitalization of about $2.12 billion, Avadel Pharmaceuticals plc is classified as a mid-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 1.90 million shares, in line with its 52-week average. Headquartered in Dublin, None, Avadel Pharmaceuticals plc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Gregory J. Divis Jr., the company employs approximately 188 people and listed since June 07, 1996. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Avadel Pharmaceuticals plc generated EPS of -$0.01 over the past year. Five-year average earnings growth is 10.39%. The latest quarter delivered EPS of $0.00. The next quarter is forecast at $0.05. Next year's EPS is expected at $78.22. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 9 Buy ratings, 7 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $12.00. The high target offers 66.44% upside. The low target suggests -44.52% downside. The mean target is $20.56. This offers -4.95% upside. Avadel Pharmaceuticals plc earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by -99.5%. The prior quarter beat by 400.0%. Over the last six quarters, Apple has recorded several small beats. These include -15.44% in August 08, 2024.

Our AI price prediction model suggests that Avadel Pharmaceuticals plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.88%, with price expected at $21.82 by February 24, 2026, within a range of $21.62 to $22.01 3-Month Outlook: Projected rise of 74.02%, reaching $37.64 by May 08, 2026, with a range of $37.33 to $38.03. 1-Year Outlook: Projected gain of 9.34%, with price at $23.65 by February 10, 2027, within a range of $22.19 to $24.80.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares are flat -0.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Avadel Pharmaceuticals plc trading at a premium to the broader market with a P/E of -7563.98. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $17.88, suggesting -17.34% downside. Our AI forecast model points to short-term strength (0.88% over two weeks), a medium-term rise (74.02% over three months), and a longer-term gain (9.34% over one year), with expected trading ranges indicating moderate volatility.

Avadel Pharmaceuticals plc trades at a P/E ratio of -7563.98, slightly below the S&P 500 average, with a price-to-sales ratio of 8.52 and a price-to-book ratio of 21.41 reflecting a rich premium to book value. The P/FCF stands at 59.83, also above market averages. Compared to sector medians, Avadel Pharmaceuticals plc P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.